MRTX vs. CORT, VKTX, CVAC, AMPH, HRMY, HCM, XENE, BBIO, RVNC, and BHC
Should you be buying Mirati Therapeutics stock or one of its competitors? The main competitors of Mirati Therapeutics include Corcept Therapeutics (CORT), Viking Therapeutics (VKTX), CureVac (CVAC), Amphastar Pharmaceuticals (AMPH), Harmony Biosciences (HRMY), HUTCHMED (HCM), Xenon Pharmaceuticals (XENE), BridgeBio Pharma (BBIO), Revance Therapeutics (RVNC), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical preparations" industry.
Mirati Therapeutics vs.
Mirati Therapeutics (NASDAQ:MRTX) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Corcept Therapeutics has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Mirati Therapeutics had 1 more articles in the media than Corcept Therapeutics. MarketBeat recorded 8 mentions for Mirati Therapeutics and 7 mentions for Corcept Therapeutics. Mirati Therapeutics' average media sentiment score of 0.76 beat Corcept Therapeutics' score of 0.67 indicating that Mirati Therapeutics is being referred to more favorably in the media.
80.1% of Corcept Therapeutics shares are owned by institutional investors. 3.5% of Mirati Therapeutics shares are owned by insiders. Comparatively, 19.8% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Mirati Therapeutics presently has a consensus target price of $68.38, indicating a potential upside of 80.05%. Corcept Therapeutics has a consensus target price of $26.71, indicating a potential upside of 14.56%. Given Mirati Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Mirati Therapeutics is more favorable than Corcept Therapeutics.
Corcept Therapeutics received 53 more outperform votes than Mirati Therapeutics when rated by MarketBeat users. Likewise, 70.43% of users gave Corcept Therapeutics an outperform vote while only 69.75% of users gave Mirati Therapeutics an outperform vote.
Corcept Therapeutics has a net margin of 22.79% compared to Mirati Therapeutics' net margin of -3,901.06%. Corcept Therapeutics' return on equity of 19.37% beat Mirati Therapeutics' return on equity.
Mirati Therapeutics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.
Summary
Corcept Therapeutics beats Mirati Therapeutics on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mirati Therapeutics Competitors List
Related Companies and Tools
